

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.41	Application No. 09/894,293
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)		Applicant		Wouter E. Roorda et al.	
		Filing Date June 27, 2001	Group Art Unit 1762		

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
jkm	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	—
	A2	4,977,901	12/18/90	Ofstead	128	772	—
	A3	5,112,457	5/12/92	Marchant	204	165	—
	A4	5,328,471	7/12/94	Slepian	604	101	—
APR 04 2003	A5	5,455,040	10/3/95	Marchant	424	426	—
	A6	5,464,650	11/7/95	Berg et al.	427	2.30	APR 8 2003 TQ 1700
	A7	5,578,073	11/26/96	Haimovich et al.	623	1	—
	A8	5,605,696	2/25/97	Eury et al.	424	423	—
	A9	5,628,730	5/13/97	Shapland et al.	604	21	—
	A10	5,667,767	9/16/97	Greff et al.	424	9.411	—
	A11	5,670,558	9/23/97	Onishi et al.	523	112	—
	A12	5,700,286	12/23/97	Tartaglia et al.	623	1	—
	A13	5,716,981	2/10/98	Hunter et al.	514	449	—
	A14	5,800,392	9/1/98	Racchini	604	96	—
	A15	5,824,049	10/20/98	Ragheb et al.	623	1	—
	A16	5,830,178	11/3/98	Jones et al.	604	49	—
	A17	5,837,313	11/17/98	Ding et al.	427	2.21	—
	A18	5,851,508	12/22/98	Greff et al.	424	9.411	—
	A19	5,858,746	1/12/99	Hubbell et al.	435	177	—
	A20	5,865,814	2/2/99	Tuch	604	265	—
	A21	5,873,904	2/23/99	Ragheb et al.	623	1	—

EXAMINER	Jennifer Kolb Michener	DATE CONSIDERED	7/25/03
----------	------------------------	-----------------	---------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) Approved for use through 10/31/2002				US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.41	Application No. 09/894,293	
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant		Wouter E. Roorda et al.		
				Filing Date		June 27, 2001	Group Art Unit 1762	
<i>Mem</i>	A22	5,971,954	10/26/99	Conway et al.		604	96	<u> </u>
<i>Office</i> <i>APR 04 2003</i>	A23	5,980,928	11/9/99	Terry		424	427	<u> </u>
<i>PTO</i> <i>TRADEMARK OFFICE</i>	A24	5,980,972	11/9/99	Ding		427	2.24	<u> </u>
	A25	6,015,541	1/18/00	Greff et al.		424	1.25	<i>RECEIVED</i> <i>TC APR 18 2003</i>
	A26	6,042,875	3/28/00	Ding et al.		427	2.24	<u> </u>
	A27	6,051,648	4/18/00	Rhee et al.		525	54.1	<u> </u>
	A28	6,056,993	5/2/00	Leidner et al.		427	2.25	<u> </u>
	A29	6,060,451	5/9/00	DiMaio et al.		514	13	<u> </u>
	A30	6,080,488	6/27/00	Hostettler et al.		428	423.3	<u> </u>
	A31	6,096,070	8/1/00	Ragheb et al.		623	1	<u> </u>
	A32	6,099,562	8/8/00	Ding et al.		623	1.46	<u> </u>
	A33	6,110,188	8/29/00	Narciso, Jr.		606	153	<u> </u>
	A34	6,113,629	9/5/00	Ken		623	1.1	<u> </u>
	A35	6,120,536	9/19/00	Ding et al.		623	1.43	<u> </u>
	A36	6,120,904	9/19/00	Hostettler et al.		428	423.3	<u> </u>
	A37	6,121,027	9/19/00	Clapper et al.		435	180	<u> </u>
	A38	6,129,761	10/10/00	Hubbell		623	11	<u> </u>
	A39	6,153,252	11/28/00	Hossainy et al.		427	2.3	<u> </u>
✓	A40	6,165,212	12/26/00	Dereume et al.		623	1.13	<u> </u>
EXAMINER	<i>Michener</i>			DATE CONSIDERED		<i>7/25/03</i>		
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.41	Application No. 09/894,293
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)		Applicant		Wouter E. Roorda et al.	
		Filing Date June 27, 2001	Group Art Unit 1762		

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
JEM	B1	EP 0 665 023	8/2/95	European	—	—	RECEIVED	APR 8 2003
	B2	EP 0 970 711	1/12/00	European	—	—	TC 1700	8/2003
SIPE	B3	WO 91/12846	9/5/91	PCT	—	—		
	B4	WO 97/45105	12/4/97	PCT	—	—		
APR 04 2003	B5	WO 99/63981	12/16/99	PCT	—	—		
PATENT TRADEMARK OFFICE	B6	WO 00/02599	1/20/00	PCT	—	—		
	B7	WO 00/12147	3/9/00	PCT	—	—		
	B8	WO 00/64506	4/21/00	PCT	—	—		
	B9	WO 01/01890 A1	6/6/00	PCT	—	—		
	B10	WO 01/45763	6/28/01	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)

C1	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury; JACC Vol. 13, No. 2; February 1989:252A (Abstract)
C2	Dichek et al., Seeding of Intravascular Stents With Genetically Engineered Endothelial Cells, Circulation 1989; 1347-1353.
C3	Forester et al., A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies; J. Am. Coll. Cardio. 1991; 17:758-769.
C4	Matsumaru et al.; Embolic Materials for Endovascular Treatment of Cerebral Lesions; J. Biomater Sci. Polymer Edn., Vol. 8, No. 7 (1997) pp. 555-569.
C5	Miyasaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice; Chem. Pharm. Bull. 33(6) (1985) pp. 2490-2498.
C6	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat; J. Cardiovasc. Pharmacol. (1997) pp. 157-162.
C7	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty; American Heart Journal (1998) pp. 1081-1087
C8	Shigeno, Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor; Chemical Abstract 125:212307 (1996).

EXAMINER

Michener

DATE CONSIDERED

7/25/03